Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats
Neuroendocrinology · 2024
DOI: 10.1159/000535365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, 2024. Verfasst von Alexandra M Vaiana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Oligopeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
Androgen deprivation therapy (ADT) is a mainstay treatment for prostate cancer, but many patients experience cognitive impairment in domains mediated by the medial prefrontal cortex (mPFC) and hippocampus. Prostate cancer typically occurs in older patients (>65 years). As age is often accompanied by cognitive decline, it may impact the efficacy of any treatment aimed at restoring cognitive impairment induced by ADT. Vortioxetine, a multimodal antidepressant that improves cognition in depression, has been shown to be efficacious in elderly patients. Therefore, vortioxetine may improve cognition in older patients who experience cognitive decline after ADT.
Methods
Young (3 months) and middle-aged (13 months) rats were used to investigate the influence of age on treating ADT-induced cognitive decline. As our previous studies used surgical castration, we tested if vortioxetine would reverse cognitive deficits associated with more translationally relevant chemical castration using degarelix. Vortioxetine was given in the diet for 21 days. Animals underwent behavioral testing to assess visuospatial memory mediated by the hippocampus and cognitive flexibility mediated by the mPFC. We also investigated changes in afferent-evoked responses in these regions in middle-aged rats.
Results
Degarelix induced impairments in both visuospatial memory and cognitive flexibility that were reversed by vortioxetine. Vortioxetine also rescued afferent-evoked responses in the mPFC and hippocampus. However, modest age-related reductions in baseline visuospatial memory limited our ability to detect further decreases induced by degarelix in middle-aged rats due to a floor effect.
Conclusion
These results suggest that vortioxetine may be a treatment option for older prostate cancer patients who experience cognitive decline after ADT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas, USA.
- Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, Texas, USA.
- Mays Cancer Center, University of Texas Health Science Center, San Antonio, Texas, USA.
- South Texas Veterans Health Care System, San Antonio, Texas, USA.
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Vaiana, A. M., Asher, A. M., Tapia, K., & Morilak, D. A. (2024). Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats. Neuroendocrinology. https://doi.org/10.1159/000535365
Vancouver
Vaiana AM, Asher AM, Tapia K, Morilak DA. Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats. Neuroendocrinology. 2024. doi:10.1159/000535365
BibTeX
@article{Vaiana2024,
author = {Vaiana, Alexandra M and Asher, Amber M and Tapia, Karla and Morilak, David A},
title = {Vortioxetine Reverses Impairment of Visuospatial Memory and Cognitive Flexibility Induced by Degarelix as a Model of Androgen Deprivation Therapy in Rats},
journal = {Neuroendocrinology},
year = {2024},
doi = {10.1159/000535365}
}
EUVIMED